Peripheral Blood CD34+ Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections Peter Gambell, Kirsten Herbert,

Slides:

Advertisements

Similar presentations

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Advertisements

Peripheral Blood Expansion of CD38 Bright CD8+ Effector Memory T-Cells Predicts Acute Graft Versus Host Disease with a Diagnostic Accuracy of 87% Pooja.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How to Treat MDS without Stem Cell Transplantation

IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies L. Lee Dupuis, Cathryn Sibbald,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma Egil S. Blix, Anders.

Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation Aaron Gerds, Mary Fox-Geiman,

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma Egil S. Blix, Anders.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Paul Shaughnessy,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Alicia Báez, Beatriz Martín-Antonio, José I

Cord Blood Units with Low CD34+ Cell Viability Have a Low Probability of Engraftment after Double Unit Transplantation Andromachi Scaradavou, Katherine.

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis Danielle H. Oh, Haocheng.

Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic.

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.

Sabina Kersting, Leo F. Verdonck

Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes J. Clausen, M. Enk, B. Vergeiner,

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962

Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation Iskra Pusic, Shi Yuan Jiang,

Let Them Eat! Comparing a Neutropenic Diet to a Food Safety Based Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Cynthia.

Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony–Stimulating Factor in Lymphoma Patients Undergoing Autologous.

Aging Impairs Long-Term Hematopoietic Regeneration after Autologous Stem Cell Transplantation Carolien M. Woolthuis, Niccoló Mariani, Rikst Nynke Verkaik-Schakel,

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing.

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation Jessica T. Stover,

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+

Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Mats Remberger, Johan Törlén, Olle.

B Cells and Transplantation: An Educational Resource

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease John A. Hansen, Samir M. Hanash, Laura Tabellini, Chris Baik, Richard L.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Comparative Analysis: Trend of Infectious Complications in Cord Blood (CB) Versus Peripheral Blood (PB) and Bone Marrow (BM) Stem Cell Transplant (SCT)

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma Katharina Lisenko,

A Randomized Controlled Trial to Compare Once- versus Twice-Daily Filgrastim for Mobilization of Peripheral Blood Stem Cells from Healthy Donors Yukiko.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value–Tailored Approach

Blood and Marrow Transplant Handbook

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.

Treatment versus Transplant for Challenging Hematologic Disorders

Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment Duncan Purtill,

Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell.

Mary Eapen Biology of Blood and Marrow Transplantation

Hematopoietic Cell Yield Declines Predictably Over Time During Apheresis Allison F. Hazlett, Elaine Wang, Jennifer Anderson, Harold Chung, John Michael.

Optimal Donor Selection: Beyond HLA

Presentation transcript:

Peripheral Blood CD34+ Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections Peter Gambell, Kirsten Herbert, Michael Dickinson, Kerrie Stokes, Mathias Bressel, Dominic Wall, Simon Harrison, H. Miles Prince Biology of Blood and Marrow Transplantation Volume 18, Issue 5, Pages 763-772 (May 2012) DOI: 10.1016/j.bbmt.2011.10.002 Copyright © 2012 Terms and Conditions

Figure 1 Single-platform CD34 ISHAGE-based gating strategy. Viable cells were analyzed using a gate based on 7AAD exclusion. A gate was then drawn on CD45+ cells (R1) to exclude noncellular debris and unlysed red cells. A gate was then drawn to capture a discrete cluster of CD34+ cells with low side scatter (R2). These cells were further refined using a homogenous cluster based on intermediate CD45+ cell expression (R3), and the CD34+ HPCs (R4) were finally defined using intermediate forward scatter (final CD34+ HPCs compared with lymphoid population follicular stem cells). The number of events in this R4 gate were compared with the number of events counted in the singlet bead gate (R7) to derive the reported CD34+ cell count. Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions

Figure 2 (A) Non–log-transformed PB CD34+ cell counts versus collection CD34+ cell counts. (B) Non–log-transformed PB CD34+ cell counts versus collection CD34+ cell counts for all samples with PB CD34+ cell count <300 × 106/L. (C) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples (after logarithmic transformation); y = −2.5712 + 0.9593x; R2 = 91.9%; P < .0001. Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions

Figure 3 (A) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients mobilized using filgrastim alone (after logarithmic transformation); y = −2.5362 + 0.9234x; R2 = 89.6%; P < .0001. (B) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients mobilized using filgrastim + chemotherapy (after logarithmic transformation); y = −2.5451 + 0.9597x; R2 = 91.6%; P < .0001. Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions

Figure 4 (A) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients weighing <70 kg (after logarithmic transformation; y = −2.5059 + 0.9508x; R2 = 90.8%; P < .0001). (B) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients weighing 70-100 kg (after logarithmic transformation; y = −2.608 + 0.9651x; R2 = 92.1%; P < .0001). (C) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients weighing >100 kg (after logarithmic transformation; y = −2.5518 + 0.9466x; R2 = 94.9%; P < .0001). Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions

Figure 5 (A) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients with WCC <20 × 109/L (after logarithmic transformation; y = −2.4500 + 0.9681x; R2 = 92.1%; P < .0001). (B) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients with WCC 20-50 × 109/L (after logarithmic transformation; y = −2.6110 + 0.9538x; R2 = 93.7%; P < .0001). (C) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients with WCC >50 × 109/L (after logarithmic transformation; y = −2.7725 + 0.9589x; R2 = 90.4%; P < .0001). Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions

Figure 6 (A) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients with a diagnosis of NHL (after logarithmic transformation; y = −2.6365 + 0.9824x; R2 = 92.1%; P < .0001). (B) Relationship between collection CD34+ cell count and PB CD34+ cell count for all samples from patients with a diagnosis of plasma cell dyscrasia (after logarithmic transformation), y = −2.5817 + 0.9616x, R2 = 92.3%, (P < .0001). (C) Relationship between collection CD34+ cells and PB CD34+ cells for all samples from patients with a diagnosis other than plasma cell dyscrasias or NHL (after logarithmic transformation; y = −2.4711 + 0.9173x; R2 = 90.0%; P < .0001). Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions

Figure 7 Boxplots showing median, 10th and 90th percentiles, maximum, and minimum CE for collections in patients with NHL, MM, and MDS/MPD. NHL versus MM: P = not significant; ∗NHL versus MDS-MPD: P = .015; ∗∗MM versus MDS-MPD: P = .019. Biology of Blood and Marrow Transplantation 2012 18, 763-772DOI: (10.1016/j.bbmt.2011.10.002) Copyright © 2012 Terms and Conditions